Bluebird falls on worries over $2.8 million gene therapy’s commercial success
By Mrinalika Roy (Reuters) -Bluebird bio slumped nearly 15% on Thursday as investors fretted over sales potential of its newly approved ultra-rare blood disorder gene therapy that is the most expensive treatment…